ABEO

Over the past six months (April 2026 - October 2026), Abeona Therapeutics reported a net loss of $(17.1) million in Q1 2026 and a net loss of $(20.2) million in Q2 2026, despite a 31% quarter-over-quarter increase in net ZEVASKYN revenue to $11.4 million. Analysts noted concerns regarding manufacturing issues that led to two out of five treated patients not generating recognized revenue. The company secured CMS New Technology Add-On Payment (NTAP) status for ZEVASKYN for fiscal year 2027, which is expected to improve hospital reimbursement. Commercial progress was indicated by the activation of new Qualified Treatment Centers for ZEVASKYN, such as Cincinnati Children's and the University of Florida Health. The company's President sold approximately $101,000 worth of stock, and Abeona participated in several healthcare conferences. In March 2026, Abeona entered a license and joint development agreement for the ABO-701 program, which included a $7 million upfront payment. The stock price has experienced declines of approximately 3.14% over the last six months, 14.97% over the last month, and 30.62% over the last three months.